APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
07/27/2026
Back to search
Official data from USPTO
ASCENTAGE PHARMA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ASCENTAGE PHARMA
ST13
US500000079246610Class
5
Filing
79246610
Registration
5876589
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
40
Latest update
08/09/2026
Trademark type
Word
Nice classes
5
Filing date
08/10/2018
Registration date
10/08/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/08/2019
Last transaction
08/09/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
98
Owner location
CN
Examiner
ENGEL, MICHAEL
Law office
L70
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
ASCENTAGE PHARMA (SUZHOU) CO., LTD.
Jiangsu Ascentage Pharma Inc.
JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.
Representatives
Kathryn E. Smith Wood Herron & Evans LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compoundsnext-generation kinase inhibitors and senolytic drugs; drugs for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; biological preparations for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; chemical preparations for pharmaceutical or medical purposesfor use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease ; medicines for dental purposes; antibiotics; pharmaceutical preparations in the form of injection for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; pharmaceutical preparations in the form of tablet for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; active pharmaceutical ingredients in the nature of drug delivery agents in the form of powdersliquidscapsules that provide controlled release of active ingredients for a wide variety of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals for treating cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; active pharmaceutical ingredients for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; biochemical medicines for the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; antiseptics; collyrium; suppositories; medicinal oils; transdermal patches for use in the treatment of cancertumorsblood-related diseasesinfectious diseasesosteoarthritisage-related diseasesfibrotic diseasesCrohn's diseasecardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; candymedicated; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic substances adapted for medical use; mineral food supplements; nutritional supplements
Publications
History of USPTO decisions and trademark events.
40 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/23/2026
ES71
TEAS SECTION 71 RECEIVED
04/07/2026
CHLD
CHANGE OF OWNER RECEIVED FROM IB
11/07/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
08/21/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
08/21/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/21/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/21/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
08/21/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
08/21/2025
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/08/2024
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/01/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/01/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/01/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/01/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/01/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/01/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
03/27/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
12/25/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
03/13/2020
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
02/03/2020
XXCR
GENERIC MADRID TRANSACTION CREATED
02/03/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/08/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
10/08/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/23/2019
PUBO
PUBLISHED FOR OPPOSITION
07/23/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/03/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/14/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/13/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/12/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/12/2019
RFNT
REFUSAL PROCESSED BY IB
01/11/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/21/2018
RFRR
REFUSAL PROCESSED BY MPU
12/20/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/11/2018
CNRT
NON-FINAL ACTION WRITTEN
12/10/2018
MAFR
APPLICATION FILING RECEIPT MAILED
12/04/2018
DOCK
ASSIGNED TO EXAMINER
11/30/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/30/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/29/2018
Continuous trademark protection
Get notified about every new filing that threatens ASCENTAGE PHARMA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.